ClinOhio Research Services, LLC | Columbus, OH

Research site

(Unclaimed)

Location

150 Taylor Station Road, Suite 100, Columbus, Ohio, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

BMS-986165

LPRI-

TAK-279

Ritlecitinib

EVO100

SAR443122

Rocatinlimab

bermekimab

Linzagolix

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 24 total trials

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidraden...

Enrolling

Hidradenitis Suppurativa

Drug: Ritlecitinib

Drug: Placebo

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Active, not recruiting

Vitiligo

Drug: Upadacitinib

Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis (ADAPTIVE)

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Enrolling

Atopic Dermatitis

Atopic Dermatitis Eczema

Drug: Placebo

Drug: IMG-007

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have bee...

Active, not recruiting

Psoriasis

Drug: Placebo

Drug: BMS-986165

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (TibuSHIELD)

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period...

Enrolling

Hidradenitis Suppurativa (HS)

Biological: Tibulizumab Dose B

Other: Placebo